AP/News-Observer Examines State Of Vaccine Research
The Associated Press/News-Observer examines revitalized vaccine research, including for such conditions as malaria, TB and HIV. “Vaccines are no longer a sleepy, low-profit niche in a booming drug industry. Today, they’re starting to give ailing pharmaceutical makers a shot in the arm,” according to the article. The AP/News-Observer looks at specific companyÂ focal pointsÂ and vaccine sales forecasts as well as how “[t]he lure of big profits, advances in technology and growing government support has been drawing in new companies, from nascent biotechs to Johnson & Johnson” to vaccines.
Emilio Emini, Pfizer’s head of vaccine research, said, “Even if a small portion of everything that’s going on now is successful in the next 10 years, you put that together with the last 10 years [and] it’s going to be characterized as a golden era.”
According to AP/News-Observer, “many companies are partnering with promising biotechs, the World Health Organization and global charities, or setting up deals with local drugmakers abroad, to inexpensively manufacture vaccines in developing and middle-tier countries that increasingly want them to prevent much-higher health care costs” (Johnson, 11/20).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.